M&A Deal Summary

Venus MedTech Acquires Cardiovalve

On December 7, 2021, Venus MedTech acquired medical products company Cardiovalve for 300M USD

Acquisition Highlights
  • This is Venus MedTech’s 2nd transaction in the Medical Products sector.
  • This is Venus MedTech’s largest (disclosed) transaction.
  • This is Venus MedTech’s 1st transaction in Israel.

M&A Deal Summary
Date 2021-12-07
Target Cardiovalve
Sector Medical Products
Buyer(s) Venus MedTech
Deal Type Add-on Acquisition
Deal Value 300M USD

Target

Cardiovalve

Or Yehuda, Israel
Cardiovalve is a transcatheter mitral and tricuspid valve treatment company that manufactures replacement products for patients suffering from mitral or tricuspid regurgitation. Cardiovalve was founded in 2010 and is based in Or Yehuda, Israel.

Search 199,713 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Venus MedTech

Hangzhou, China
Category Company
Founded 2009
Sector Medical Products
Employees1,028
Revenue 416M HKD (2021)
DESCRIPTION

Venus MedTech is a medical device company that develops and commercializes artificial aortic valve products. Venus MedTech was founded in 2009 and is based in Hangzhou, China.

DEAL STATS #
Overall 2 of 2
Sector (Medical Products) 2 of 2
Type (Add-on Acquisition) 2 of 2
Country (Israel) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-06-14 InterValve

Minnetonka, Minnesota, United States

InterValve, Inc. is a medical device company that designs and develops aortic valvuloplasty balloon for the treatment of calcific aortic stenosis. InterValve, Inc. was founded in 2008 and is based in Minnetonka, Minnesota.

Buy -
Mergr

Product

Company

Legal